Contact

Paxman publishes newsletter on the company’s relaunch in the Canadian market

Today, Paxman publishes the September issue of its newsletter aimed at shareholders, investors and other interested parties.

This month’s issue highlights that Paxman is relaunching its Canadian business, with a new business model similar to the one being used in the United States. The company will also use a more direct approach, with patient technicians to support patients on site. 30+ patients have been treated so far, and scalp cooling systems have been installed at three cancer centers in Toronto.

The newsletter also includes information on that 10 units of Paxman’s CIPN system will be delivered to National University of Singapore (NUS) before the end of the months for initial testing on healthy volunteers, that the company’s Italian distribution partner Praesidia has ordered 10 PSCS2 systems, and CEO Richard Paxman answers shareholder questions on the Q2 interim report.

To read the newsletter and subscribe for upcoming issues, follow this link:

http://bit.ly/paxsep21en

Paxman’s investor newsletter is published monthly as a part of the company’s effort to strengthen its market communication together with the IR communication agency Honeybadger. Every published issue of the newsletter is available on Paxman’s website for investors, www.paxman.se. The company encourages feedback and requests on topics for upcoming issues of the newsletter.

What we do
Paxman are world leaders in chemotherapy side effect management on an ambitious journey to change the face of cancer through cryotherapy-based treatments. The Paxman mission is to democratise access to scalp cooling globally.
Learn more →
Financial Information
Read the latest Paxman financial reports. In these comprehensive documents, you will find a detailed overview of our financial performance, key milestones, and a strategic outlook for the future. Reports are published quarterly and annually.
Read reports  →
Investing in Paxman
Paxman has treated 100,000+ patients and installed 5,000+ systems in more than 65 countries worldwide. We are helping to manage the trauma of chemotherapy hair loss. By investing in Paxman, you're not just supporting a company; you're joining us in changing the face of cancer.
Visit the Investor Centre →
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram